Open | $6.400 |
Close | $6.760 |
Volume / Avg. | 527.162K / 252.534K |
Day Range | 6.100 - 6.910 |
52 Wk Range | 2.680 - 8.221 |
Market Cap | $213.518M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 85 |
Short Interest | 8.72% |
Days to Cover | 18.74 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Capricor Therapeutics (NASDAQ: CAPR) through any online brokerage.
Other companies in Capricor Therapeutics’s space includes: Innate Pharma (NASDAQ:IPHA), Graphite Bio (NASDAQ:GRPH), FibroGen (NASDAQ:FGEN), GlycoMimetics (NASDAQ:GLYC) and Genelux (NASDAQ:GNLX).
The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on Friday, March 1, 2024. The analyst firm set a price target for 40.00 expecting CAPR to rise to within 12 months (a possible 488.24% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $6.8 last updated March 18, 2024 at 4:52 PM EDT.
There are no upcoming dividends for Capricor Therapeutics.
Capricor Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Capricor Therapeutics.
Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.